<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2022-12-22 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Controlled Correspondence Related to Generic Drug Development." This guidance provides information regarding the process by which generic drug manufacturers and related industry can submit controlled correspondence to FDA requesting information related to generic drug development and the Agency's process for providing communications related to such correspondence. This guida...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-27827</p>
    <p><strong>Publication Date:</strong> 2022-12-22</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/12/22/2022-27827/controlled-correspondence-related-to-generic-drug-development-draft-guidance-for-industry">https://www.federalregister.gov/documents/2022/12/22/2022-27827/controlled-correspondence-related-to-generic-drug-development-draft-guidance-for-industry</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-27827</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
